EUVIMEDEUVIMED entdecken
Crossref

MYC gene amplification drives protein overexpression and its clinical prognostic value in prostate cancer: a study of 152 Chinese cases

Mei Tang, Chunyan Xie, Rongfei Huang, Chuanfen Lei, Xianjing Yu, Ping Zhou

American Journal of Clinical Pathology · 04.06.2026 · 165 (6)

DOI: 10.1093/ajcp/aqag059 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Clinical Pathology, online erschienen am 17.06.2026. Verfasst von Mei Tang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, West China School of Public Health and West China Fourth Hospital, Sichuan University, Chengdu, Sichuan Province, China. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Gene Amplification, Adenocarcinoma, Biomarkers, Tumor. Die Arbeit nennt 55 Literaturangaben. Gefördert von: Horizontal Project of West China Fourth Hospital, Sichuan University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

To investigate the expression patterns of ERG, PTEN, and c-Myc proteins in prostate adenocarcinoma; analyze the status of the MYC gene; and evaluate their correlations with clinicopathologic parameters and patient prognosis.

Methods

In this retrospective study, 152 prostate adenocarcinoma cases were analyzed. Immunohistochemistry was performed for ERG, PTEN, and c-Myc protein expression. Fluorescence in situ hybridization was used to assess ERG rearrangement, MYC gene breakage, and amplification. Statistical analyses were conducted to evaluate associations between molecular markers and clinicopathologic variables, as well as their impact on survival outcomes.

Results

The positive expression rates for ERG, PTEN, and c-Myc high expression (immunoreactive score ≥5) were 9.9%, 86.8%, and 50%, respectively. The detection rate of MYC gene amplification was 27.6%. Both c-Myc high expression and MYC gene amplification were significantly associated with the high-grade group (defined as Grade Group ≥3 and/or with cribriform pattern), lymphovascular invasion, advanced T stage, metastasis, and poor prognosis, with gene amplification demonstrating higher prognostic specificity. ERG protein expression was significantly correlated with PTEN positivity, whereas no significant association was found between MYC gene amplification and ERG protein expression; only a nonsignificant mutually exclusive trend was observed. Conclusions c-Myc activation, particularly MYC gene amplification, is a key driver and specific biomarker for an aggressive phenotype and poor prognosis in prostate adenocarcinoma. Combined detection of ERG, PTEN, and c-Myc status contributes to refining risk stratification systems. The lack of significant association between MYC amplification and ERG expression suggests they may represent distinct oncogenic pathways, warranting further validation in large prospective studies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsGene AmplificationAdenocarcinomaBiomarkers, TumorProto-Oncogene Proteins c-mycGenes, mycHumansMalePrognosisRetrospective StudiesAgedMiddle AgedPTEN PhosphohydrolaseTranscriptional Regulator ERGIn Situ Hybridization, FluorescenceImmunohistochemistryAged, 80 and overTrans-ActivatorsEast Asian People

Stichwörter der Autor:innen

Chinese populationERGMYC gene amplificationPTENfluorescence in situ hybridizationimmunohistochemistryprognostic biomarkerprostate cancerrisk stratification

Substanzen

Biomarkers, TumorProto-Oncogene Proteins c-mycPTEN PhosphohydrolaseTranscriptional Regulator ERGERG protein, humanPTEN protein, humanMYC protein, humanTrans-Activators

Autor:innen und Institutionen

  • Department of Pathology, West China School of Public Health and West China Fourth Hospital, Sichuan University, Chengdu, Sichuan Province, China.
  • Department of Pathology, Mianyang Central Hospital, Mianyang, Sichuan Province, China.

Förderung

  • Horizontal Project of West China Fourth Hospital, Sichuan University

Zitieren

APA

Tang, M., Xie, C., Huang, R., Lei, C., Yu, X., & Zhou, P. (2026). MYC gene amplification drives protein overexpression and its clinical prognostic value in prostate cancer: a study of 152 Chinese cases. American Journal of Clinical Pathology, 165(6). https://doi.org/10.1093/ajcp/aqag059

Vancouver

Tang M, Xie C, Huang R, Lei C, Yu X, Zhou P. MYC gene amplification drives protein overexpression and its clinical prognostic value in prostate cancer: a study of 152 Chinese cases. American Journal of Clinical Pathology. 2026;165(6). doi:10.1093/ajcp/aqag059

BibTeX
@article{Tang2026,
  author = {Tang, Mei and Xie, Chunyan and Huang, Rongfei and Lei, Chuanfen and Yu, Xianjing and Zhou, Ping},
  title = {MYC gene amplification drives protein overexpression and its clinical prognostic value in prostate cancer: a study of 152 Chinese cases},
  journal = {American Journal of Clinical Pathology},
  year = {2026},
  volume = {165},
  number = {6},
  doi = {10.1093/ajcp/aqag059}
}
Kostenlos starten →